InvestorsHub Logo
Followers 14
Posts 469
Boards Moderated 0
Alias Born 07/29/2010

Re: The Other Guy post# 314662

Thursday, 10/19/2017 5:24:12 PM

Thursday, October 19, 2017 5:24:12 PM

Post# of 346050

$1.78 pre RS. Sadly Johnson/Swartz/Pohl/King made a disastrous mistake by going it alone and we pay the price



Could not agree more. Would be good to know if this decision was due to low-ball offers or the company asking too much. With the right partner helping to fund multiple trials we would have stood a much better chance of finding out if PS targeting could be an important component in emerging IO therapies. They greedily bet the farm (at our expense) on the Ph3 trial.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News